Why XOMA Corp. Shares Tanked

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of XOMA (NASDAQ: XOMA  ) , a biopharmaceutical company focused on developing antibody-based therapeutics, dipped as much as 19% on the day after reporting its first-quarter earnings results after the closing bell last night.

So what: For the quarter, XOMA produced revenue of $3.4 million, down 64% from the year-ago period when it delivered $9.5 million in revenue. XOMA blamed the drop on reduced reimbursements from Servier associated with gevokizumab's development activities. As noted in its press release, Servier met its end of the bargain by paying for the initial $50 million in gevokizumab development costs. Now, XOMA shares those costs with Servier 50-50. Net loss for the quarter, excluding warrant value changes, grew to $24.7 million, or $0.23 per share, from $12 million, or $0.15 per share, in the year-prior period. Comparatively, Wall Street was expecting a narrower loss of just $0.17 per share.

Shares were also under pressure after a price-target downgrade from Ladenburg Thalmann to $8 from $10 after the company announced that slow patient enrollment may delay the completion of its EYEGUARD-C trial beyond the end of this year. XOMA had initially planned to complete the trial by year's end.

Now what: The disappointments just keep racking up for XOMA with a wider-than-expected loss, and a potential delay in its EYEGUARD-C trial. Keep in mind that this follows the March swoon after it discontinued its mid-stage study of gevokizumab as a treatment for erosive osteoarthritis of the hand, or EOA. There's definitely a lot of potential indications for gevokizumab, and one therapy can often have a marked different effect from one disease indication to another, so there's still a lot of hope even after its failure in EOA. However, as an investor, I'd suggest sticking to the sidelines until we have something more concrete to go off of than just "hope."

XOMA may offer world's of potential, but even it could be no match for this top stock over the long haul
Give me five minutes, and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer handpicks one stock with outstanding potential. But it's not just any run-of-the-mill company; it’s a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% during the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.


Read/Post Comments (1) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2950225, ~/Articles/ArticleHandler.aspx, 8/27/2014 5:24:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement